Illumina (NASDAQ:ILMN) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Illumina (NASDAQ:ILMN) from a hold rating to a buy rating in a research note issued to investors on Saturday.

Other equities research analysts have also issued research reports about the stock. Weiss Ratings reissued a “sell (d+)” rating on shares of Illumina in a research report on Wednesday, October 8th. Morgan Stanley upped their price target on shares of Illumina from $100.00 to $105.00 and gave the stock an “equal weight” rating in a research report on Monday, August 4th. Barclays raised their price objective on Illumina from $95.00 to $100.00 and gave the company an “underweight” rating in a research report on Friday, October 31st. Robert W. Baird set a $109.00 price objective on Illumina in a research note on Friday, October 31st. Finally, Royal Bank Of Canada set a $124.00 target price on Illumina in a research note on Tuesday, September 2nd. Five investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, Illumina presently has a consensus rating of “Hold” and a consensus price target of $115.00.

Illumina Stock Performance

Illumina stock opened at $121.72 on Friday. The company has a market cap of $18.60 billion, a price-to-earnings ratio of 15.41, a price-to-earnings-growth ratio of 2.34 and a beta of 1.42. Illumina has a 12 month low of $68.70 and a 12 month high of $153.06. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41. The stock’s 50-day moving average is $100.95 and its 200-day moving average is $94.88.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.16 by $0.18. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The firm had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter in the prior year, the company earned $1.14 EPS. The company’s revenue was up .4% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. Equities analysts anticipate that Illumina will post 4.51 earnings per share for the current year.

Insider Transactions at Illumina

In related news, Director Scott Gottlieb acquired 500 shares of Illumina stock in a transaction on Monday, November 3rd. The shares were purchased at an average cost of $122.13 per share, for a total transaction of $61,065.00. Following the purchase, the director directly owned 12,523 shares of the company’s stock, valued at $1,529,433.99. The trade was a 4.16% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Illumina

Hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its stake in Illumina by 3.5% in the first quarter. Vanguard Group Inc. now owns 16,371,662 shares of the life sciences company’s stock worth $1,298,928,000 after purchasing an additional 558,243 shares in the last quarter. WCM Investment Management LLC raised its stake in Illumina by 5.9% during the second quarter. WCM Investment Management LLC now owns 4,426,471 shares of the life sciences company’s stock valued at $419,585,000 after buying an additional 247,460 shares in the last quarter. Loomis Sayles & Co. L P lifted its holdings in Illumina by 1.9% during the 2nd quarter. Loomis Sayles & Co. L P now owns 4,225,529 shares of the life sciences company’s stock worth $403,158,000 after buying an additional 78,317 shares during the last quarter. Corvex Management LP grew its position in shares of Illumina by 125.2% in the 1st quarter. Corvex Management LP now owns 3,829,608 shares of the life sciences company’s stock worth $303,841,000 after acquiring an additional 2,129,449 shares in the last quarter. Finally, AQR Capital Management LLC grew its position in shares of Illumina by 55.3% in the 2nd quarter. AQR Capital Management LLC now owns 3,295,880 shares of the life sciences company’s stock worth $313,290,000 after acquiring an additional 1,174,295 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.